Clinical pharmacology: A paradigm for individualized medicine

Scott A. Waldman, Walter K. Kraft, Timothy J Nelson, Andre Terzic

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Individualized medicine provides a powerful engine revolutionizing the practice of clinical pharmacology, tailoring genetic and molecular profiles of patients to improve therapeutic specificity, reduce treatment variability and minimize adverse drug events. In that context, advances in individualized medicine have transformed the science of clinical pharmacology and therapeutics from drug discovery through identification of drugable targets, development through stratification of disease risk, regulation through identifying pathways mediating off-target effects and utilization through personalizing drug regimens. This revolution in fundamental and applied therapeutics has entrained an evolution in biology and medicine. Insights in the mechanistic basis of cell, tissue and organ function, and their interface with the environment are being translated to define disease risk, identify processes mediating disease susceptibility, target mechanism-based therapies, and tailor prevention and control paradigms, providing previously unanticipated opportunities for patient-specific disease management. The emerging field of individualized medicine is transforming the practice of clinical pharmacology, driving the leading edge of discovery from the laboratory bench to the evidence basis of practice in the clinic, extending to populations, to transform healthcare and create predictive, personalized and pre-emptive solutions for tailored patient-specific therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)679-684
Number of pages6
JournalBiomarkers in Medicine
Volume3
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Precision Medicine
Clinical Pharmacology
Medicine
Therapeutics
Pharmaceutical Preparations
Disease Susceptibility
Drug Discovery
Tissue
Disease Management
Engines
Drug-Related Side Effects and Adverse Reactions
Molecular Biology
Delivery of Health Care
Population

Keywords

  • Clinical pharmacology
  • Individualized medicine
  • Molecular diagnostics
  • Personalized medicine
  • Targeted therapeutics

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery

Cite this

Clinical pharmacology : A paradigm for individualized medicine. / Waldman, Scott A.; Kraft, Walter K.; Nelson, Timothy J; Terzic, Andre.

In: Biomarkers in Medicine, Vol. 3, No. 6, 2009, p. 679-684.

Research output: Contribution to journalArticle

Waldman, Scott A. ; Kraft, Walter K. ; Nelson, Timothy J ; Terzic, Andre. / Clinical pharmacology : A paradigm for individualized medicine. In: Biomarkers in Medicine. 2009 ; Vol. 3, No. 6. pp. 679-684.
@article{c279c737eec541f68511744b97b5eacd,
title = "Clinical pharmacology: A paradigm for individualized medicine",
abstract = "Individualized medicine provides a powerful engine revolutionizing the practice of clinical pharmacology, tailoring genetic and molecular profiles of patients to improve therapeutic specificity, reduce treatment variability and minimize adverse drug events. In that context, advances in individualized medicine have transformed the science of clinical pharmacology and therapeutics from drug discovery through identification of drugable targets, development through stratification of disease risk, regulation through identifying pathways mediating off-target effects and utilization through personalizing drug regimens. This revolution in fundamental and applied therapeutics has entrained an evolution in biology and medicine. Insights in the mechanistic basis of cell, tissue and organ function, and their interface with the environment are being translated to define disease risk, identify processes mediating disease susceptibility, target mechanism-based therapies, and tailor prevention and control paradigms, providing previously unanticipated opportunities for patient-specific disease management. The emerging field of individualized medicine is transforming the practice of clinical pharmacology, driving the leading edge of discovery from the laboratory bench to the evidence basis of practice in the clinic, extending to populations, to transform healthcare and create predictive, personalized and pre-emptive solutions for tailored patient-specific therapeutic strategies.",
keywords = "Clinical pharmacology, Individualized medicine, Molecular diagnostics, Personalized medicine, Targeted therapeutics",
author = "Waldman, {Scott A.} and Kraft, {Walter K.} and Nelson, {Timothy J} and Andre Terzic",
year = "2009",
doi = "10.2217/bmm.09.76",
language = "English (US)",
volume = "3",
pages = "679--684",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Clinical pharmacology

T2 - A paradigm for individualized medicine

AU - Waldman, Scott A.

AU - Kraft, Walter K.

AU - Nelson, Timothy J

AU - Terzic, Andre

PY - 2009

Y1 - 2009

N2 - Individualized medicine provides a powerful engine revolutionizing the practice of clinical pharmacology, tailoring genetic and molecular profiles of patients to improve therapeutic specificity, reduce treatment variability and minimize adverse drug events. In that context, advances in individualized medicine have transformed the science of clinical pharmacology and therapeutics from drug discovery through identification of drugable targets, development through stratification of disease risk, regulation through identifying pathways mediating off-target effects and utilization through personalizing drug regimens. This revolution in fundamental and applied therapeutics has entrained an evolution in biology and medicine. Insights in the mechanistic basis of cell, tissue and organ function, and their interface with the environment are being translated to define disease risk, identify processes mediating disease susceptibility, target mechanism-based therapies, and tailor prevention and control paradigms, providing previously unanticipated opportunities for patient-specific disease management. The emerging field of individualized medicine is transforming the practice of clinical pharmacology, driving the leading edge of discovery from the laboratory bench to the evidence basis of practice in the clinic, extending to populations, to transform healthcare and create predictive, personalized and pre-emptive solutions for tailored patient-specific therapeutic strategies.

AB - Individualized medicine provides a powerful engine revolutionizing the practice of clinical pharmacology, tailoring genetic and molecular profiles of patients to improve therapeutic specificity, reduce treatment variability and minimize adverse drug events. In that context, advances in individualized medicine have transformed the science of clinical pharmacology and therapeutics from drug discovery through identification of drugable targets, development through stratification of disease risk, regulation through identifying pathways mediating off-target effects and utilization through personalizing drug regimens. This revolution in fundamental and applied therapeutics has entrained an evolution in biology and medicine. Insights in the mechanistic basis of cell, tissue and organ function, and their interface with the environment are being translated to define disease risk, identify processes mediating disease susceptibility, target mechanism-based therapies, and tailor prevention and control paradigms, providing previously unanticipated opportunities for patient-specific disease management. The emerging field of individualized medicine is transforming the practice of clinical pharmacology, driving the leading edge of discovery from the laboratory bench to the evidence basis of practice in the clinic, extending to populations, to transform healthcare and create predictive, personalized and pre-emptive solutions for tailored patient-specific therapeutic strategies.

KW - Clinical pharmacology

KW - Individualized medicine

KW - Molecular diagnostics

KW - Personalized medicine

KW - Targeted therapeutics

UR - http://www.scopus.com/inward/record.url?scp=75149196043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149196043&partnerID=8YFLogxK

U2 - 10.2217/bmm.09.76

DO - 10.2217/bmm.09.76

M3 - Article

C2 - 20477706

AN - SCOPUS:75149196043

VL - 3

SP - 679

EP - 684

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 6

ER -